Zenith Epigenetics

Zenith Epigenetics is a biotechnology company developing bromodomain (BET) inhibitors for the treatment of cancer and other disorders. It offers a pan selective BET inhibitor for patients suffering from solid tumors, including prostate cancer.
TypeSubsidiary
HQSan Francisco, CA, US
Founded2013
Websitezenithepigenetics.com
Cybersecurity ratingAMore
Zenith Epigenetics was founded in 2013 and is headquartered in San Francisco, CA, US

Viewing summary data as a guest

Sign up for free to see all data
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Zenith Epigenetics

Donald J. McCaffrey

Donald J. McCaffrey

President and Chief Executive Officer, Chairman of the Board
Kelly McNeill

Kelly McNeill

Director
Sanjay Lakhotia

Sanjay Lakhotia

Chief Business Officer
Eldon R. Smith

Eldon R. Smith

Director
Henrik C. Hansen

Henrik C. Hansen

Senior Vice President of Operations
Brad Cann

Brad Cann

Chief Financial Officer
Show more

Zenith Epigenetics Office Locations

Zenith Epigenetics has offices in San Francisco and Calgary
San Francisco, CA, US (HQ)
44 Montgomery, 44 Montgomery St #4010, San Francisco
Calgary, CA
4820 Richard Rd SW #300
Show all (2)

Zenith Epigenetics Financials and Metrics

Summary Metrics

Founding Date

2013

Total Funding

$16.6 m
In total, Zenith Epigenetics had raised $16.6 m

Zenith Epigenetics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

92/100

SecurityScorecard logo

Zenith Epigenetics Online and Social Media Presence

Embed Graph

Zenith Epigenetics News and Updates

Zenith Epigenetics and Newsoara Announce Initiation of a Randomized Phase 2b Metastatic Castration-Resistant Prostate Cancer (mCRPC) Study

Evaluating the Combination of ZEN-3694 and Enzalutamide in mCRPC Patients Who Responded Poorly to Prior Abiraterone Treatment Evaluating the Combination of ZEN-3694 and Enzalutamide in mCRPC Patients Who Responded Poorly to Prior Abiraterone Treatment

Zenith Epigenetics Announces Dosing of First mCRPC Patient with a Combination of ZEN-3694 + Merck’s Immune Check Point Inhibitor KEYTRUDA

Novel UCSF investigator led Phase 2 clinical study to address role of epigenetic therapy in mitigating resistance to immune-oncology drugs Novel UCSF investigator led Phase 2 clinical study to address role of epigenetic therapy in mitigating resistance to immune-oncology drugs

Zenith Epigenetics Frequently Asked Questions

  • When was Zenith Epigenetics founded?

    Zenith Epigenetics was founded in 2013.

  • Who are Zenith Epigenetics key executives?

    Zenith Epigenetics's key executives are Donald J. McCaffrey, Kelly McNeill and Sanjay Lakhotia.

  • How many employees does Zenith Epigenetics have?

    Zenith Epigenetics has 13 employees.

  • Who are Zenith Epigenetics competitors?

    Competitors of Zenith Epigenetics include GenCirq, Theranyx and Neumedicines.

  • Where is Zenith Epigenetics headquarters?

    Zenith Epigenetics headquarters is located at 44 Montgomery, 44 Montgomery St #4010, San Francisco, San Francisco.

  • Where are Zenith Epigenetics offices?

    Zenith Epigenetics has offices in San Francisco and Calgary.

  • How many offices does Zenith Epigenetics have?

    Zenith Epigenetics has 2 offices.